Enzymebiosystems (ENZB) 0.0300 $ENZB EnzymeBioSystems

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Enzymebiosystems (ENZB) 0.0300 $ENZB

EnzymeBioSystems Product Development Update
PR Newswire - Thu Aug 20, 12:30PM CDT
EnzymeBioSystems (OTCBB: ENZB - News) announces that while it continues its early-stage research to obtain an Investigational New Drug Application for methyl amooranin, a product the prevention of breast cancer, management is pursuing other opportunities for the Company.

Amooranin completes preclinical sample batch of methyl amooranin for reduction of breast tumors
M2 - Tue Jul 28, 5:54AM CDT
Enzymes company EnzymeBioSystems (OTC BB:ENZB) reported on Monday that it has completed a preclinical methyl amooranin batch in the prevention of breast cancer.

Amooranin Preclinical Sample Batch Completed
PR Newswire - Mon Jul 27, 5:41PM CDT
EnzymeBioSystems (OTC BB: ENZB - News) announces that a preclinical methyl amooranin batch has been completed. Amooranin is the Company's lead pharmaceutical product. EnzymeBioSystems plans to seek approval for the use of methyl amooranin in the prevention of breast cancer.

Penny Stocks Reports for EnzymeBioSystems, Sigma Labs, NanoTech Entertainment, Anavex Life Sciences, BIRCHCLIFF, and Pharmacyte Biotech
PR Newswire - Fri Mar 20, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: EnzymeBioSystems (OTCBB:ENZB), Sigma Labs (OTCMKTS:SGLB), NanoTech Entertainment (OTCMKTS:NTEK), Anavex Life Sciences (OTCMKTS:AVXL), BIRCHCLIFF (OTCMKTS:BIREF), and Pharmacyte Biotech (OTCMKTS MCB).
AVXL: 5.89 (-0.22)

EnzymeBioSystems Cleared for OTCQB Listing
ACCESSWIRE - Mon Mar 16, 12:12PM CDT
LAS VEGAS, NV / ACCESSWIRE / March 16, 2015 / EnzymeBioSystems (OTCQB: ENZB) announced that it received notice of approval from OTC Markets Group, Inc. ("OTC Markets" that its stock will be listed on OTCQB Marketplace, effective March 16, 2015. ENZB submitted all the mandatory documents and has met all requirements for listing on the OTCQB Marketplace.

Market Maker Surveillance Report. NNBR, IDT, CTRV, ENZB, HTBX, ESCRP, Losing Stocks With Lowest Price Friction For Tuesday, March 10th 2015
M2 - Wed Mar 11, 4:18AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4960 companies with "abnormal" market making, 1371 companies with positive Friction Factors and 5291 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. NN Inc (NASDAQ:NNBR), IDT Corp (NYSE:IDT), CARDILLO TRAVEL SYS (NASDAQ:CTRV), EnzymeBioSystems (OTC:ENZB), (NASDAQ:HTBX), (NASDAQ:ESCRP). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
HTBX: 0.72 (+0.01), CTRV: 1.08 (+0.04), IDT: 14.61 (+0.42), ESCRP: 0.45 (+0.04), NNBR: 14.16 (+0.17)

EnzymeBioSystems' Amooranin preclinical sample batch to be completed by end of February 2015
M2 - Thu Feb 19, 5:13AM CST
Specialist enzymes company EnzymeBioSystems (OTCBB:ENZB) revealed on Wednesday that its preclinical methyl amooranin batch for the prevention of breast cancer nears completion.

Amooranin Preclinical Sample Batch Nears Completion
ACCESSWIRE - Wed Feb 11, 7:00AM CST
LAS VEGAS, NV / ACCESSWIRE / February 11, 2015 / EnzymeBioSystems (OTC:ENZB) announces that its preclinical methyl amooranin batch nears completion. Amooranin is the Company's lead pharmaceutical product. The Company plans to seek the use of methyl amooranin in the prevention of breast cancer.

Preclinical Xenograft Studies Show Positive Results For Amooranin
PR Newswire - Wed Dec 10, 12:45PM CST
EnzymeBioSystems (OTCBB: ENZB) announces that preclinical xenograft studies with methyl amooranin, its lead pharmaceutical product, show positive results in inhibiting human colon carcinoma.

EnzymeBioSystems Announces an Independent Research Group Reported Breast Cancer Preventive Efficacy for a Novel Synthetic Triterpenoid
PR Newswire - Mon Nov 17, 7:30AM CST
EnzymeBioSystems (OTCBB: ENZB) announces, methyl amooranin, its lead pharmaceutical product, shows promise in preventing breast cancer. Based on preclinical research lead by Dr. Anupam Bishayee, Associate Professor, Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove, CA, methyl amooranin markedly inhibited breast tumor formation in an animal model of breast cancer that mimics human disease. The results were published by the peer-reviewed journal International Journal of Cancer (September 1, 2013 edition). Two additional published studies from Dr. Bishayee's laboratory also looked at possible mechanisms of action of this promising compound in preventing breast cancer. Dr. Bishayee's research was supported by a grant from National Institutes of Health (NIH)/National Cancer Institute (NCI).

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Managed Connectivity: Key to Modern Multifamily Living

Updated Category News Views 5

Connectivity Runs the Modern Show Imagine moving into a shiny new apartment, where the biggest hassle isn't unpacking boxes but ensuring your gadgets get online smoothly. That's the reality of today's multifamily living, where the internet is more than a utility—it's the backbone of modern life. And if you think it's just about offering internet access, you're missing...

Continue Reading
Ultrabench Revolutionizes AI Model Comparison Game

Updated Category News Views 3

Breaking Down the Messy AI Model Landscape Ultrabench.ai is here to drag AI model comparison out of the dark ages. Picture this: 309 AI models, ranked against a whopping 530 benchmarks, all served up on one plate. If you’re navigating the AI jungle, you’ll realize how Ultrabench is no small fish in this vast ocean. Consolidating Where Others Have Scattered There's a...

Continue Reading
Li-Fire Expands Fire Safety Amid Rising Battery Risks

Updated Category News Views 7

A Crunchy Look at New Fire Safety Moves Well, folks, here's a twist we didn't see coming but sure makes sense in today's electrifying business landscape. Li-Fire, the big brains behind lithium battery fire suppression, is spreading its wings nationwide, or at least its wholesale and distribution programs are. And right ahead of National Fire Safety Week no less—talk...

Continue Reading
Maternal Health Index: A New Tool With Big Ambitions

Updated Category News Views 6

A Fresh Take on Maternal Health Today's all about the Heartland Forward's fresh tool, the Maternal Resiliency Index. It's making a splash at the 2026 Heartland Summit with a lot of promise on its shoulders. Backed by economists and health gurus like Emily Oster and Dr. Neel Shah, this index ain't your run-of-the-mill tool. It's here to shake the couch coins out of...

Continue Reading
Kroger, Imprint Team Up for AI-Driven Mastercard

Updated Category News Views 4

Kroger Teams Up with Imprint for New Credit Card Kroger’s at it again, folks. They're rolling out a shiny new Mastercard, and it's not just any plastic—it’s powered by the AI-driven platform Imprint. Now, what does this mean for you and me? Well, if you're a frequent flyer at Kroger aisles, you might want to pay attention because this card’s offering point...

Continue Reading
Gateway Unveils All-In-One Award Travel Platform

Updated Category News Views 7

Transforming Loyalty with point.me's Gateway Here's the deal: the loyalty program game just changed. Point.me rolled out this slick beast called Gateway, and it's weaving award travel booking right into your everyday banking apps. That's right, ditch those clunky third-party sites, because now you can browse, compare, transfer, and book your award travel directly from...

Continue Reading
New Tools Arm Manufacturers in Additive Arena

Updated Category News Views 3

Diving Headfirst into Additive Manufacturing Standards Additive manufacturing (AM)—it's not just another tech buzzword. It's revolutionizing everything from life-saving medical devices to cutting-edge aerospace components. But as with any game-changing innovation, there's a wild west era before standards reign in the chaos. Enter ANSI and America Makes, offering new...

Continue Reading
Rochester Memorial Installations: Key Timelines Revealed

Updated Category News Views 6

There are times in life where patience isn’t just a virtue, it’s a necessity—memorial installations are one of those instances. In Rochester, NY, folks dealing with the loss of a loved one want more than just closures; they want to commemorate their people in a way that lasts. But how long does it take, really, to set these tributes in stone? Understanding the...

Continue Reading
MiniCo's New Desk: A Game Changer for E&S Market

Updated Category News Views 4

A New Chapter in Industrial Casualty Look out, folks! MiniCo Insurance Agency is making waves with its latest launch. They're teaming up with Lloyd's of London, not to sell fish and chips, but to bring something groundbreaking in the insurance space—an industrial casualty trading desk. And if you’re raising an eyebrow wondering why this matters, let me break it down...

Continue Reading
Haystack MRD Shines in Colorectal Cancer Trials

Updated Category News Views 5

A New Dawn in Cancer Detection Just when you think you've seen it all in cancer diagnostics, Haystack MRD® pops up like a fresh tulip in spring. And listen, this ain't just fluff—the results from the DYNAMIC trials are a pretty compelling love letter to the power of liquid biopsy. With 100% specificity and sensitivity hitting a whopping 83.3% over five years, it’s...

Continue Reading

Top 5 Most Recently Viewed Articles

UBS Analysts Predict Gold Prices to Soar by 2025

Updated Category News Views 336

Gold's Predicted Rise in 2025 According to Analysts In an insightful analysis, experts from UBS suggest that gold prices are poised to reach another record high in 2025. With growing concerns around market volatility, investors are increasingly looking for safe-haven assets, and gold tops that list. A Strong Surge in Gold Prices Recent data indicates that gold experienced...

Continue Reading
Saratoga Investment Corp. Announces $0.75 Dividend for 2026

Updated Category News Views 118

Saratoga Investment Corp. Declares a Monthly Dividend In a recent announcement, Saratoga Investment Corp. (NYSE: SAR) revealed that it will pay dividends totaling $0.75 per share for the third quarter of fiscal 2026. This will be distributed as monthly dividends of $0.25 each, demonstrating the company's ongoing commitment to delivering consistent returns to its...

Continue Reading
Icahn Enterprises L.P. Set to Host Third Quarter Earnings Call

Updated Category News Views 230

Icahn Enterprises L.P. Plans Q3 2024 Earnings Call Icahn Enterprises L.P. (NASDAQ: IEP) is excited to announce it will be hosting a conference call to discuss its third-quarter results for 2024. The call is scheduled to be conducted via webcast on an upcoming Friday morning, giving investors an opportunity to gain insights into the company's financial performance. Webcast...

Continue Reading
Crown Crafts to Present at IDEAS Investor Conference

Updated Category News Views 90

Crown Crafts to Present at IDEAS Investor Conference GONZALES, La. — Crown Crafts, Inc. (NASDAQ-CM: CRWS) has announced that Olivia W. Elliott, the President and Chief Executive Officer, along with Craig J. Demarest, the Vice President and Chief Financial Officer, will be presenting at the 15th Annual Midwest IDEAS Investor Conference on a date to be determined. The...

Continue Reading
Transforming $1,000 Investment into $6,200 with Marvell Tech

Updated Category News Views 37

How a $1,000 Investment in Marvell Tech Yields Over $6,200 Marvell Technology, known by its stock ticker MRVL, has made waves in the financial world over the past decade. With an impressive market performance, this company has outshined many of its competitors, showcasing the power of strategic investment. Investors fortunate enough to have invested in Marvell Tech ten...

Continue Reading